| Nov 8 |
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
|
| Nov 8 |
Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib
|
| Nov 7 |
FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment
|
| Nov 7 |
J&J wins approval of Varipulse atrial fibrillation device
|
| Nov 7 |
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
|
| Nov 7 |
J&J wins FDA approval for Varipulse PFA system
|
| Nov 5 |
Johnson & Johnson Darzalex shows efficacy in early-stage multiple myeloma
|
| Nov 5 |
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
|
| Nov 5 |
With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners
|
| Nov 4 |
Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?
|
